MA56049A - Formulations stabilisées contenant des anticorps anti-angptl3 - Google Patents

Formulations stabilisées contenant des anticorps anti-angptl3

Info

Publication number
MA56049A
MA56049A MA056049A MA56049A MA56049A MA 56049 A MA56049 A MA 56049A MA 056049 A MA056049 A MA 056049A MA 56049 A MA56049 A MA 56049A MA 56049 A MA56049 A MA 56049A
Authority
MA
Morocco
Prior art keywords
formulations containing
containing anti
stabilized formulations
angptl3 antibodies
angptl3
Prior art date
Application number
MA056049A
Other languages
English (en)
Inventor
Dingjiang Liu
Andria Skinner
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA56049A publication Critical patent/MA56049A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA056049A 2019-05-24 2020-05-24 Formulations stabilisées contenant des anticorps anti-angptl3 MA56049A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962852643P 2019-05-24 2019-05-24

Publications (1)

Publication Number Publication Date
MA56049A true MA56049A (fr) 2022-04-06

Family

ID=72179136

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056049A MA56049A (fr) 2019-05-24 2020-05-24 Formulations stabilisées contenant des anticorps anti-angptl3

Country Status (17)

Country Link
US (1) US12559551B2 (fr)
EP (1) EP3976647A1 (fr)
JP (1) JP7783051B2 (fr)
KR (1) KR20220011727A (fr)
CN (1) CN114007647A (fr)
AU (1) AU2020282956A1 (fr)
BR (1) BR112021023501A2 (fr)
CA (1) CA3139333A1 (fr)
CL (1) CL2021003026A1 (fr)
CO (1) CO2021016183A2 (fr)
EA (1) EA202193240A1 (fr)
IL (1) IL288153A (fr)
MA (1) MA56049A (fr)
MX (1) MX2021014332A (fr)
PH (1) PH12021552788A1 (fr)
SG (1) SG11202112256SA (fr)
WO (1) WO2020243031A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
KR102456731B1 (ko) 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
CA3055583A1 (fr) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injecteur
EP4306103B1 (fr) * 2021-03-09 2025-12-24 GI Innovation, Inc. Formulation de protéine de fusion comprenant le domaine extracellulaire de sous-unité alpha du récepteur fc d'ige
EP4375298A4 (fr) * 2021-07-21 2025-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Composition pharmaceutique d'anticorps anti-angptl3 ou de fragment de liaison à l'antigène de celui-ci et son application
US20230193271A1 (en) 2021-12-22 2023-06-22 Regeneron Pharmaceuticals, Inc. Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) Inhibitors
WO2023213779A1 (fr) 2022-05-02 2023-11-09 Novo Nordisk A/S Nouveaux anticorps anti-angptl3 appropriés pour des compositions à concentration élevée et administration sous-cutanée
AU2023375521A1 (en) 2022-11-10 2025-05-15 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors
US20250108173A1 (en) 2023-10-02 2025-04-03 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
WO2026051789A1 (fr) * 2024-09-03 2026-03-12 四川科伦博泰生物医药股份有限公司 Protéine de liaison de pcsk9 et angptl3, et utilisation de protéine de liaison

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
WO2000047734A1 (fr) 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibition de la formation des lesions atherosclereuses
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
AU2001259099B2 (en) 2001-02-22 2005-12-22 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
EP1451578B1 (fr) 2001-11-16 2013-08-21 Genentech, Inc. Utilisation d' antagonistes de angptl3 pour le traitement des maladies inflammatoires du foie
EP2322203A3 (fr) 2002-10-29 2011-07-27 Genentech, Inc. Les compositions et les methodes pour le traitement de maladies liees immunisees
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
CN101855241B (zh) 2006-12-08 2013-11-06 莱克康制药公司 针对angptl3的单克隆抗体
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
DK2398476T3 (en) 2009-02-23 2018-04-16 Nanorx Inc POLICOSANOL NANOPARTICLES
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PL2453921T3 (pl) 2009-07-14 2015-11-30 Scripps Research Inst Różnicowanie mezenchymalnych komórek macierzystych
EP2521556B1 (fr) 2010-01-08 2018-05-30 Ionis Pharmaceuticals, Inc. Modulation de l'expression de l'analogue de l'angiopoïétine 3
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN103890000B (zh) 2011-06-21 2017-09-01 阿尔尼拉姆医药品有限公司 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
WO2013012022A1 (fr) * 2011-07-19 2013-01-24 中外製薬株式会社 Préparation à teneur en protéines stable renfermant de l'argininamide ou un composé analogue correspondant
CN106421782A (zh) 2012-10-25 2017-02-22 米迪缪尼有限公司 稳定的低粘度抗体配制品
BR112015022624A2 (pt) 2013-03-14 2017-10-31 Uab Research Foundation regime de dose, e, método para tratamento de aterosclerose
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
EA201691039A1 (ru) 2013-11-20 2016-11-30 Саймабэй Терапьютикс, Инк. Лечение гомозиготной семейной гиперхолестеринемии
CN105814204B (zh) 2013-12-24 2020-04-28 Ionis制药公司 促血管生成素样3表达的调节
ES2844593T3 (es) 2014-05-01 2021-07-22 Ionis Pharmaceuticals Inc Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
EP3169362B1 (fr) 2014-07-16 2020-06-10 Sanofi Biotechnology Méthodes de traitement de patients présentant un risque cardiovasculaire élevé avec hypercholestérolémie
US10071139B2 (en) 2014-10-03 2018-09-11 Ngm Biopharmaceuticals, Inc. Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
ES2951262T3 (es) 2016-02-17 2023-10-19 Regeneron Pharma Métodos para tratar o prevenir la aterosclerosis mediante la administración de un inhibidor de ANGPTL3
KR102456731B1 (ko) 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
LT3439689T (lt) 2016-04-08 2021-11-10 Regeneron Pharmaceuticals, Inc. Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
CA3021884A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methodes de traitement de patients presentant une hypercholesterolemie familiale
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP2023538522A (ja) 2020-08-07 2023-09-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法

Also Published As

Publication number Publication date
US12559551B2 (en) 2026-02-24
SG11202112256SA (en) 2021-12-30
CA3139333A1 (fr) 2020-12-03
CN114007647A (zh) 2022-02-01
AU2020282956A1 (en) 2022-01-27
IL288153A (en) 2022-01-01
WO2020243031A1 (fr) 2020-12-03
US20200369760A1 (en) 2020-11-26
MX2021014332A (es) 2022-04-06
JP2022532927A (ja) 2022-07-20
CL2021003026A1 (es) 2022-06-24
KR20220011727A (ko) 2022-01-28
BR112021023501A2 (pt) 2022-01-18
CO2021016183A2 (es) 2021-12-10
JP7783051B2 (ja) 2025-12-09
EA202193240A1 (ru) 2022-03-14
PH12021552788A1 (en) 2022-09-28
EP3976647A1 (fr) 2022-04-06

Similar Documents

Publication Publication Date Title
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
MA55362A (fr) Formulations stabilisées contenant des anticorps anti-il-33
MA49043A (fr) Formulation stable d'anticorps
EP3449940A4 (fr) Préparation contenant un anticorps
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3581651A4 (fr) Anticorps anti-gprc5d et molécule le contenant
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EP3825404A4 (fr) Car contenant un anticorps monocaténaire anti-gpc3
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
MA51903A (fr) Formulations d'anticorps b7-h4
EP3823978A4 (fr) Compositions d'anticorps anti-fcrn
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA54052A (fr) Formulation d'anticorps
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA54139A (fr) Formulation d'anticorps
EP3995582A4 (fr) Anticorps anti-epha4
EP3831851A4 (fr) Anticorps anti-btla
EP3394099A4 (fr) Formulations d'anticorps anti-il-10 modifiés
MA53466A (fr) Formulation stable d'anticorps anti-osmr